| Year |
Citation |
Score |
| 2024 |
Bartlett MJ, Stopera CJ, Cowen SL, Sherman SJ, Falk T. Differential effects of statins on the anti-dyskinetic activity of sub-anesthetic ketamine. Biorxiv : the Preprint Server For Biology. PMID 39651168 DOI: 10.1101/2024.11.26.625570 |
0.702 |
|
| 2024 |
Vishwanath A, Bartlett MJ, Falk T, Cowen SL. Decoupling of motor cortex to movement in Parkinson's dyskinesia rescued by sub-anaesthetic ketamine. Brain : a Journal of Neurology. PMID 39585797 DOI: 10.1093/brain/awae386 |
0.684 |
|
| 2024 |
Zadina JE, Szabo LZ, Al-Obeidi F, Zhang X, Ferreira Nakatani L, Ogbu C, Heien ML, Falk T, Bartlett MJ, Polt R. Cyclic Glycopeptide Analogs of Endomorphin-1 Provide Highly Effective Antinociception in Male and Female Mice. Acs Medicinal Chemistry Letters. 15: 1731-1740. PMID 39411536 DOI: 10.1021/acsmedchemlett.4c00315 |
0.669 |
|
| 2024 |
Bernard K, Mota JA, Wene P, Corenblum MJ, Saez JL, Bartlett MJ, Heien ML, Doyle KP, Polt R, Hay M, Madhavan L, Falk T. The angiotensin (1-7) glycopeptide PNA5 improvescognition in achronic progressive mouse model of Parkinson's disease through modulation of neuroinflammation. Experimental Neurology. 114926. PMID 39153685 DOI: 10.1016/j.expneurol.2024.114926 |
0.675 |
|
| 2024 |
Stopera CJ, Bartlett MJ, Liu C, Esqueda A, Parmar R, Heien ML, Sherman SJ, Falk T. Differential effects of opioid receptor antagonism on the anti-dyskinetic and anti-parkinsonian effects of sub-anesthetic ketamine treatment in a preclinical model. Neuropharmacology. 257: 110047. PMID 38889877 DOI: 10.1016/j.neuropharm.2024.110047 |
0.731 |
|
| 2023 |
Jordan GA, Vishwanath A, Holguin G, Bartlett MJ, Tapia AK, Winter GM, Sexauer MR, Stopera CJ, Falk T, Cowen SL. Automated system for training and assessing reaching and grasping behaviors in rodents. Journal of Neuroscience Methods. 109990. PMID 37866457 DOI: 10.1016/j.jneumeth.2023.109990 |
0.622 |
|
| 2023 |
Flores AJ, Bartlett MJ, Seaton BT, Samtani G, Sexauer MR, Weintraub NC, Siegenthaler JR, Lu D, Heien ML, Porreca F, Sherman SJ, Falk T. Antagonism of kappa opioid receptors accelerates the development of L-DOPA-induced dyskinesia in a preclinical model of moderate dopamine depletion. Brain Research. 1821: 148613. PMID 37783263 DOI: 10.1016/j.brainres.2023.148613 |
0.74 |
|
| 2023 |
Flores AJ, Bartlett MJ, Seaton BT, Samtani G, Sexauer MR, Weintraub NC, Siegenthaler JR, Lu D, Heien ML, Porreca F, Sherman SJ, Falk T. Antagonism of kappa opioid receptors worsens the development of L-DOPA-induced dyskinesia in a preclinical model of moderate dopamine depletion. Biorxiv : the Preprint Server For Biology. PMID 37577558 DOI: 10.1101/2023.07.31.551112 |
0.74 |
|
| 2023 |
Jordan GA, Vishwanath A, Holguin G, Bartlett MJ, Tapia AK, Winter GM, Sexauer MR, Stopera CJ, Falk T, Cowen SL. Automated system for training and assessing string-pulling behaviors in rodents. Biorxiv : the Preprint Server For Biology. PMID 37461637 DOI: 10.1101/2023.07.02.547431 |
0.618 |
|
| 2023 |
Szabó LZ, Tanguturi P, Goodman HJ, Sprőber S, Liu C, Al-Obeidi F, Bartlett MJ, Falk T, Kumirov VK, Heien ML, Streicher JM, Polt R. Structure-Based Design of Glycosylated Oxytocin Analogues with Improved Selectivity and Antinociceptive Activity. Acs Medicinal Chemistry Letters. 14: 163-170. PMID 36793431 DOI: 10.1021/acsmedchemlett.2c00455 |
0.665 |
|
| 2022 |
Apostol CR, Bernard K, Tanguturi P, Molnar G, Bartlett MJ, Szabò L, Liu C, Ortiz JB, Saber M, Giordano KR, Green TRF, Melvin J, Morrison HW, Madhavan L, Rowe RK, et al. Design and Synthesis of Brain Penetrant Glycopeptide Analogues of PACAP With Neuroprotective Potential for Traumatic Brain Injury and Parkinsonism. Frontiers in Drug Discovery. 1. PMID 35237767 DOI: 10.3389/fddsv.2021.818003 |
0.686 |
|
| 2021 |
Pottenger AE, Bartlett MJ, Sherman SJ, Falk T, Morrison HW. Evaluation of microglia in a rodent model of Parkinson's disease primed with L-DOPA after sub-anesthetic ketamine treatment. Neuroscience Letters. 136251. PMID 34536508 DOI: 10.1016/j.neulet.2021.136251 |
0.73 |
|
| 2021 |
Ye T, Bartlett MJ, Sherman SJ, Falk T, Cowen SL. Spectral signatures of L-DOPA-induced dyskinesia depend on L-DOPA dose and are suppressed by ketamine. Experimental Neurology. 113670. PMID 33662379 DOI: 10.1016/j.expneurol.2021.113670 |
0.752 |
|
| 2021 |
Young KF, Gardner R, Sariana V, Whitman SA, Bartlett MJ, Falk T, Morrison HW. Can quantifying morphology and TMEM119 expression distinguish between microglia and infiltrating macrophages after ischemic stroke and reperfusion in male and female mice? Journal of Neuroinflammation. 18: 58. PMID 33618737 DOI: 10.1186/s12974-021-02105-2 |
0.599 |
|
| 2020 |
Bartlett MJ, Mabrouk OS, Szabò L, Flores AJ, Parent KL, Bidlack JM, Heien ML, Kennedy RT, Polt R, Sherman SJ, Falk T. The Delta-Specific Opioid Glycopeptide BBI-11008: CNS Penetration and Behavioral Analysis in a Preclinical Model of Levodopa-Induced Dyskinesia. International Journal of Molecular Sciences. 22. PMID 33374986 DOI: 10.3390/ijms22010020 |
0.731 |
|
| 2020 |
Bartlett MJ, Flores AJ, Ye T, Smidt SI, Dollish HK, Stancati JA, Farrell DC, Parent KL, Doyle KP, Besselsen DG, Heien ML, Cowen SL, Steece-Collier K, Sherman SJ, Falk T. Preclinical evidence in support of repurposing sub-anesthetic ketamine as a treatment for L-DOPA-induced dyskinesia. Experimental Neurology. 113413. PMID 32717354 DOI: 10.1016/J.Expneurol.2020.113413 |
0.766 |
|
| 2020 |
Crown LM, Bartlett MJ, Wiegand JL, Eby AJ, Monroe EJ, Gies K, Wohlford L, Fell MJ, Falk T, Cowen SL. Sleep Spindles and Fragmented Sleep as Prodromal Markers in a Preclinical Model of LRRK2-G2019S Parkinson's Disease. Frontiers in Neurology. 11: 324. PMID 32477237 DOI: 10.3389/Fneur.2020.00324 |
0.633 |
|
| 2020 |
Bartlett MJ, So LY, Szabò L, Skinner DP, Parent KL, Heien ML, Vanderah TW, Polt R, Sherman SJ, Falk T. Highly-selective µ-opioid receptor antagonism does not block L-DOPA-induced dyskinesia in a rodent model. Bmc Research Notes. 13: 149. PMID 32164786 DOI: 10.1186/S13104-020-04994-7 |
0.732 |
|
| 2019 |
Hay M, Polt R, Heien ML, Vanderah TW, Largen-Milnes TM, Rodgers KE, Falk T, Bartlett MJ, Doyle K, Konhilas J. A Novel Angiotensin-(1-7)-glycosylated Mas Receptor Agonist for Treating Vascular Cognitive Impairment and Inflammation Related Memory Dysfunction. The Journal of Pharmacology and Experimental Therapeutics. PMID 30709867 DOI: 10.1124/Jpet.118.254854 |
0.683 |
|
| 2018 |
Flores AJ, Bartlett MJ, Root BK, Parent KL, Heien ML, Porreca F, Polt R, Sherman SJ, Falk T. The combination of the opioid glycopeptide MMP-2200 and a NMDA receptor antagonist reduced l-DOPA-induced dyskinesia and MMP-2200 by itself reduced dopamine receptor 2-like agonist-induced dyskinesia. Neuropharmacology. 141: 260-271. PMID 30201210 DOI: 10.1016/J.Neuropharm.2018.09.005 |
0.736 |
|
| 2018 |
Ye T, Bartlett MJ, Schmit MB, Sherman SJ, Falk T, Cowen SL. Ten-Hour Exposure to Low-Dose Ketamine Enhances Corticostriatal Cross-Frequency Coupling and Hippocampal Broad-Band Gamma Oscillations. Frontiers in Neural Circuits. 12: 61. PMID 30150926 DOI: 10.3389/Fncir.2018.00061 |
0.735 |
|
| 2015 |
Bartlett MJ, Joseph RM, LePoidevin LM, Parent KL, Laude ND, Lazarus LB, Heien ML, Estevez M, Sherman SJ, Falk T. Long-term effect of sub-anesthetic ketamine in reducing L-DOPA-induced dyskinesias in a preclinical model. Neuroscience Letters. PMID 26644333 DOI: 10.1016/J.Neulet.2015.11.047 |
0.72 |
|
| 2014 |
Flores AJ, Bartlett MJ, So LY, Laude ND, Parent KL, Heien ML, Sherman SJ, Falk T. Differential effects of the NMDA receptor antagonist MK-801 on dopamine receptor D1- and D2-induced abnormal involuntary movements in a preclinical model. Neuroscience Letters. 564: 48-52. PMID 24525249 DOI: 10.1016/J.Neulet.2014.02.004 |
0.731 |
|
| 2014 |
Yue X, Hariri DJ, Caballero B, Zhang S, Bartlett MJ, Kaut O, Mount DW, Wüllner U, Sherman SJ, Falk T. Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinson's disease. Neuroscience. 258: 385-400. PMID 24291725 DOI: 10.1016/J.Neuroscience.2013.11.038 |
0.692 |
|
| Show low-probability matches. |